This review proposes that K2's higher adverse effect incidence is thanks, not less than in part, to distinct JWH-018 metabolite action at the cannabinoid 1 receptor (CB1R), and indicates that metabolites of most prescription drugs, but not the carboxy metabolite, retain in vitro and in vivo action at CB1Rs. Springer https://mam-220142085.blogdon.net/5-tips-about-am-2201-you-can-use-today-47342262